Meeting
2024 ASCO Genitourinary Cancers Symposium
Real-life data on [177Lu]Lu-PSMA-617: Descriptive analysis on the largest metastatic castration-resistant prostate cancer (mCRPC) cohort treated in France.
Authors
Guilhem Roubaud
Department of Medical Oncology, Institut Bergonié, Bordeaux, France
Guilhem Roubaud , François Somme , Philippe Barthelemy , Pierre Olivier , Vincent Massard , Anne Laure Giraudet , Aude Flechon , Sylvie Girault , Sophie Abadie Lacourtoisie , Clément Bailly , Caroline Viala , Yann Godbert
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Therapeutics
Citation
J Clin Oncol 42, 2024 (suppl 4; abstr 129)
DOI
10.1200/JCO.2024.42.4_suppl.129
Abstract #
129
Poster Bd #
E22
Abstract Disclosures
Similar Posters
Poster
2024 ASCO Genitourinary Cancers Symposium
Predictors of PSA response to Lu177-PSMA-617 in metastatic castration-resistant prostate cancer.
First Author: Rebecca Hassoun
Poster
2020 ASCO Virtual Scientific Program
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
First Author: Evan Y. Yu
Poster
2020 Genitourinary Cancers Symposium
A multicenter, randomized, controlled phase II study: Efficacy and safety of PSMA-targeted radioligand therapy I-131-1095 (1095) plus enzalutamide (enza) in 18F-DCFPyL PSMA scan avid, metastatic castration-resistant prostate cancer (mCRPC) patients post-abiraterone (abi) progression (ARROW).
First Author: Evan Y. Yu
Poster
2014 ASCO Annual Meeting
A phase 2 trial of prostate-specific membrane antigen antibody drug conjugate (PSMA ADC) in taxane-refractory metastatic castration-resistant prostate cancer (mCRPC).
First Author: Daniel Peter Petrylak